Literature DB >> 7767490

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features.

P Gambetti1, P Parchi, R B Petersen, S G Chen, E Lugaresi.   

Abstract

Fatal familial insomnia (FFI) and a subtype of familial Creutzfeldt-Jakob disease (CJD178) are two prion diseases that have different clinical and pathological features, the same aspartic acid to asparagine mutation (D178N) at codon 178 of the prion protein (PrP) gene, but distinct genotypes generated by the methionine-valine polymorphism at codon 129 (129M or 129V) in the mutant allele of the PrP gene. The D178N, 129M allele segregates with FFI while the D178N, 129V allele segregates with CJD178. The proteinase K resistant PrP (PrPres) isoforms present in FFI and CJD178 differ in degree of glycosylation and size. Thus, the amino acid, methionine or valine, at position 129 of the mutant allele, in conjunction with D178N mutation results in significant alterations of PrPres in FFI and CJD178. The 129 polymorphic site also exerts influence through the normal allele: the course of the disease is shorter in the patients homozygous at codon 129 and other minor but consistent phenotypic differences occur between homozygous and heterozygous FFI patients. The comparative study of PrPres distribution in FFI homozygotes and heterozygotes at codon 129 has lead to the conclusion that the phenotypic differences observed between these two FFI patient populations may be the result of different rates of conversion of normal PrP into PrPres, at least in some brain regions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767490     DOI: 10.1111/j.1750-3639.1995.tb00576.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  33 in total

Review 1.  Prions.

Authors:  David W Colby; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

2.  Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation.

Authors:  Ana B Rodríguez-Martínez; Miguel A Alfonso-Sánchez; José A Peña; Raquel Sánchez-Valle; Inga Zerr; Sabina Capellari; Miguel Calero; Juan J Zarranz; Marian M de Pancorbo
Journal:  Neurogenetics       Date:  2008-03-18       Impact factor: 2.660

3.  Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease.

Authors:  L Cervenáková; L G Goldfarb; R Garruto; H S Lee; D C Gajdusek; P Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 4.  Prion diseases: what will be next?

Authors:  P van der Valk
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

5.  Sleep and sleep regulation in normal and prion protein-deficient mice.

Authors:  I Tobler; T Deboer; M Fischer
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

6.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

Review 7.  The Unexposed Secrets of Prion Protein Oligomers.

Authors:  Gailing Wang; Mingcheng Wang; Chuanfeng Li
Journal:  J Mol Neurosci       Date:  2015-04-01       Impact factor: 3.444

8.  Contributions of neuronal prion protein on sleep recovery and stress response following sleep deprivation.

Authors:  Manuel Sánchez-Alavez; Bruno Conti; Gianluca Moroncini; José R Criado
Journal:  Brain Res       Date:  2007-05-22       Impact factor: 3.252

9.  Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease.

Authors:  Jennifer Williamson; Susan LaRusse
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

10.  T188K-Familial Creutzfeldt-Jacob Disease, Predominant Among Chinese, has a Reactive Pattern in CSF RT-QuIC Different from D178N-Fatal Familial Insomnia and E200K-Familial CJD.

Authors:  Kang Xiao; Qi Shi; Wei Zhou; Bao-Yun Zhang; Yuan Wang; Cao Chen; Yue Ma; Chen Gao; Xiao-Ping Dong
Journal:  Neurosci Bull       Date:  2019-03-05       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.